OBD is a revenue-generating biotechnology company focused on the discovery and development of novel biomarkers for use within the biotechnology and pharmaceutical industries.

Our proprietary technology, EpiSwitch®, has multiple, immediate applications across a number of therapeutic areas and indications, including oncology, autoimmune disease, immunotherapy, metabolic and neurodegenerative conditions and can be used on an industrial scale to:

  • Reduce time to market, failure rates and the costs at every stage of drug discovery, from pre-clinical through to clinical development.
  • Gain significant insights into disease mechanisms for drug discovery and product re-positioning programmes, as well as for the creation of predictive, diagnostic and prognostic tests.
  • Personalise therapeutics to patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Our strategic aim is to become the biomarker discovery technology platform of choice. By integrating EpiSwitch® within the drug development process we enable pharmaceutical and biotechnology companies to increase the success rate of drug trials and reduce the overall cost of drug development.